Table 5 Treatments and outcomes
From: Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma
Patients | Treatment1 | PFS1 | Treatment2 | PFS2 | Treatment3 | PFS3 | Treatment 4 | PFS3 | Treatment5 | PFS4 | Outcomes | OS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Surgery | 1 m | Atezo | 2w | – | – | – | – | – | – | dead | 1.5 m |
2 | TP | 3 × 21d | Gefitinib | 2w | Apatinib | 1 m | – | – | – | – | dead | 4.1 m |
3 | TP | 2 × 21d | T | 1 × 21d | T + Nivo | 1 × 21d | – | – | – | – | dead | 3 m |
4 | TP | 21d |  |  |  |  |  |  |  |  | dead | 1.5 m |
5 | RT | 1 m | Pembro | 7 × 21d(5 m) | Support care | 13 m | – | – | – | – | dead | 19.5 m |
6 | Cet + DP + CCR | 6 × 21d | Support care | 18 m | Pembro+Cet | 4 × 21d | Pembro+ oxaliplatin | 1 × 21d | Support care | – | dead | 26.7 m |
7 | DP + Cet | 2 × 21d | G + T + Nivo Pembro+Nivo+GT | 2w 2 × 14d | Nivo+Iri + P | 21d | Pembro+CBP + R | 3 m | Support care | – | Alive | 12 m+ |